Sorry, you need to enable JavaScript to visit this website.

Resistance to Treatments | SYMTUZA® (darunavir/cobicistat/emtricitabine/tenofovir alafenamide) HCP

M184V/I Prevalence

Emerging High-Level Resistance May Impact Future Treatment Options

An analysis of resistance data revealed that

M184V/I was present in 31% of samples in 2017

M184V/I can predict significant resistance to the backbone component of many currently prescribed STRs2

High-level resistance appeared in all ARV drug classes among treatment-experienced patients1

Emerging DRMs graph displaying percentage of patients who developed high-level DRMs

*The presence of drug resistance mutations may not correlate with clinical outcomes.

ARV=antiretroviral; DRM=drug resistance mutation; INSTI=integrase strand transfer inhibitor; NNRTI=non-nucleoside reverse transcriptase inhibitor; NRTI=nucleoside reverse transcriptase inhibitor; PI=protease inhibitor; STR=single tablet regimen.

References: 1. Kagan RM, Dunn KJ, Snell GP, et al. Trends in HIV-1 drug resistance mutations from a U.S. reference laboratory from 2006 to 2017. AIDS Res Hum Retroviruses. 2019;35(8):698-709. 2. Department of Health and Human Services. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Updated January 20, 2022. Accessed March 8, 2022.

You may be interested in: